{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'The sponsor will implement two testing hierarchies based on the two different indication labels', 'for the US and US reference countries and the EU and EU reference countries. Accordingly, for', 'the US and US reference countries, the testing hierarchy will start with baseline blood eosinophils', '>300 cells/L population; For EU and EU reference countries, the testing hierarchy will start with', 'type 2 inflammatory phenotype population (patients with baseline blood eosinophils', '>150 cells/uL or baseline FeNO >20 ppb). For more details about multiplicity consideration, refer', 'to Section 11.4.2.3.', 'The efficacy analyses will be conducted according to the treatment to which they are randomized.', 'Selected efficacy endpoints will also be analyzed based on the full ITT population. More details', 'will be specified in the SAP.', '11.3.2 Safety Population', 'The analysis population for the safety endpoints will be safety population defined as all patients', 'exposed to study medication, regardless of the amount of treatment administered and regardless of', 'whether they are randomized. The safety analyses will be conducted according to the treatment', 'patients actually received.', 'Treatment emergent period for safety population is defined as the time between the first', 'administration of study medication to the end of the Post-treatment Period or till the rollover to', 'the 1-year long-term extension study.', 'In addition:', 'Randomized patients for whom it is unclear whether they took the study medication will', 'be included in the safety population as randomized.', '11.3.3 Systemic Drug Concentration Population', 'The systemic drug concentration population will consist of all patients in the safety population', 'with at least one evaluable functional dupilumab concentration result. Patients will be analyzed', 'according to the treatment actually received.', '11.3.4 Anti-drug Antibody (ADA) Population', 'The ADA population will consist of all patients in the safety population with at least one qualified', 'ADA result in the ADA assay following the first dose of the study medication. Patients will be', 'analyzed according to the treatment actually received.', 'Property of the Sanofi Group - strictly confidential', 'Page 111', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '11.4 STATISTICAL METHODS', '11.4.1 Extent of Study Treatment Exposure and Compliance', 'The extent of study treatment exposure and compliance will be assessed and summarized by', 'actual treatment received within the safety population.', '11.4.1.1 Extent of Investigational Medicinal Product Exposure', 'Duration of IMP exposure is defined as: last dose date - first dose date + 14 days, regardless of', 'unplanned intermittent discontinuations.', '11.4.1.2 Compliance', 'An administration is considered compliant if an injection is performed with the planned dose as', 'required by the protocol. No imputation will be made for patients with missing or incomplete', 'data. When an administration is given with a dose above the planned dose, the corresponding', 'administration is defined as above-planned dose noncompliance. When an administration is given', 'with a dose below the planned dose, the corresponding administration is defined as below-planned', 'dose noncompliance. Percentage of treatment compliance, above-planned dose and below-planned', 'dose non-compliance will be summarized descriptively (N, Mean, standard deviation [SD],', 'Median, Min, and Max). The percentage of patients with compliance is <80% will be', 'summarized.', '11.4.2 Analyses of Efficacy Enpoints', 'Annualized rate of severe asthma exacerbation events during the 52 weeks is the primary efficacy', 'endpoint of this study. Key secondary endpoints include change from baseline in', 'pre-bronchodilator % predicted FEV1 at Weeks 12. Other secondary endpoints include change', 'from baseline in pre-bronchodilator % predicted FEV1 at Weeks 2, 4, 8, 24, 36 and 52 and other', 'time points in between; time to first severe exacerbation event; time to first LOAC event; change', 'from baseline in other lung function measurements (absolute and relative FEV1, AM/PM PEF,', 'FVC, FEF 25-75%, post-bronchodilator % predicted FEV1 at Weeks 2, 4, 8, 12, 24, 36, 52, and', 'other time-points in between; change from baseline at Weeks 2, 4, 8, 12, 24, 36, 52, and other', 'time-points for morning/evening asthma symptom score and nocturnal awakenings (electronic', 'diary), use of reliever medication, and ACQ score. Change from baseline for PAQLQ(S)-IA', 'score, PACQLQ score, PRQLQ-IA score (in those with history of allergic rhinitis) and health care', 'resource utilization, will be assessed at Weeks 12, 24, 36, 52, 64; and percentage of patients', 'requiring increase in dose or addition of background medication.', 'In addition to the primary approach to analyze change from baseline in ACQ-IA and', 'PAQLQ(S)-IA total score, supportive responder analyses will also be performed for these', 'endpoints at Week 12, 24, 36, 52 and 64. Details of these analyses will be provided in the', 'statistical analysis plan.', 'Property of the Sanofi Group - strictly confidential', 'Page 112', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}